Tomoko Kawai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoko Kawai has a total of 547 co-authors. Here are the top co-authors by number of shared publications:
Kazuhito Rokutan
23 shared publications- Kenichiro Hata
Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo 157-8535, Japan
20 shared publications Kenichiro Hata
Department of Maternal‐Fetal Biology National Center for Child Health and Development Setagaya‐ku Tokyo Japan
17 shared publications- Kensei Nishida
Department of Pathophysiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
15 shared publications Kazuhiko Nakabayashi
Department of Maternal–Fetal Biology, National Center for Child Health and Development, Tokyo, Japan
13 shared publicationsKiyoshi Masuda
A Department of Pathophysiology , Institute of Biomedical Sciences, Tokushima University Graduate School , Tokushima , Japan
13 shared publications
Latest Publications
- 15 November 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (11)
Fetal Hypophosphatasia Caused by ALPL Variants Mimicking Severe Osteogenesis Imperfecta
The prenatal imaging features of severe osteogenesis imperfecta and perinatal hypophosphatasia substantially overlap, making their differentiation challenging. We present a case of a female fetus initially suspected of having severe osteogenesis imperfecta owing to prominent early long‐bone bowing and relatively preserved calvarial ossification detected on prenatal ultrasound. Trio‐based exome sequencing established a diagnosis of autosomal recessive perinatal hypophosphatasia by identifying compound heterozygous pathogenic variants in the ALPL gene. The initial misdiagnosis based solely on imaging highlights the substantial phenotypic overlap between these two distinct skeletal dysplasias. This case emphasizes that perinatal hypophosphatasia can mimic osteogenesis imperfecta in utero. Therefore, when fetal imaging shows ambiguous skeletal findings, molecular testing is indispensable for accurate prenatal diagnosis, optimal perinatal management, and precise genetic counseling.
- 15 November 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (11)
Fetal Hypophosphatasia Caused by ALPL Variants Mimicking Severe Osteogenesis Imperfecta
The prenatal imaging features of severe osteogenesis imperfecta and perinatal hypophosphatasia substantially overlap, making their differentiation challenging. We present a case of a female fetus initially suspected of having severe osteogenesis imperfecta owing to prominent early long‐bone bowing and relatively preserved calvarial ossification detected on prenatal ultrasound. Trio‐based exome sequencing established a diagnosis of autosomal recessive perinatal hypophosphatasia by identifying compound heterozygous pathogenic variants in the ALPL gene. The initial misdiagnosis based solely on imaging highlights the substantial phenotypic overlap between these two distinct skeletal dysplasias. This case emphasizes that perinatal hypophosphatasia can mimic osteogenesis imperfecta in utero. Therefore, when fetal imaging shows ambiguous skeletal findings, molecular testing is indispensable for accurate prenatal diagnosis, optimal perinatal management, and precise genetic counseling.
- Open Access
CREBBP variants underlying Menke–Hennekam syndrome exhibit histone acetyltransferase hyperactivity with divergent phase behaviors
Menke–Hennekam syndrome (MKHK) is a neurodevelopmental disease characterized by specific pathogenic regions within the transcriptional coactivator CREB-binding protein ( CREBBP ). CREBBP regulates gene expression through histone acetyltransferase (HAT) activity and involves IDR-dependent transcriptional condensates. Although domain-specific phenotypes and distinct DNA methylation episignatures have been recognized in MKHK, the underlying molecular mechanisms remain widely unclear. In this study, we identified a recurrent missense variant, p.(R1868W) [R1868W] and a novel splice variant r.5963_5969del,p.(Cys1723Thrfs*19) [C1723fs] in two families clinically diagnosed with MKHK and manifesting developmental delay, characteristic facial features, and growth impairment. R1868W and C1723fs exhibited increased auto-, nonhistone protein, and histone acetylation. Despite these shared enzymatic abnormalities, the variants promoted divergent disruption in liquid–liquid phase separation. The recurrent CBP-ID4 variant R1868W activated the formation of low-mobility aberrant nuclear condensates, whereas the C-terminal, truncating variant C1723fs, impaired condensate formation and showed diffuse nuclear localization. Treatment with the selective p300/CBP HAT inhibitor A485 partially restored condensate dynamics and fusion-relaxation behavior in R1868W. Furthermore, R1868W recruited BRD4 around condensates in an acetylation-dependent manner, which was suppressed by the BET inhibitor JQ1. Together, these findings suggest that aberrant condensate material properties arising from disrupted CREBBP IDR-dependent regulation play a critical role in the molecular pathogenesis of MKHK. Significance Statement: Pathogenic variants in specific regions of the transcriptional coactivator CREBBP underlie the Menke–Hennekam syndrome (MKHK), but its molecular basis is poorly understood. Here, we show that two CREBBP variants responsible for MKHK share a common feature of increased histone acetyltransferase (HAT) activity but disrupt liquid–liquid phase separation in distinct ways. The recurrent CBP-ID4 missense variant R1868W promoted the formation of low-mobility aberrant condensates and acetylation-dependent recruitment of BRD4, as opposed to the C-terminal truncating variant C1723fs. Notably, HAT inhibition restored condensate dynamics in R1868W, suggesting that condensate properties are reversibly regulated by enzymatic activity. These findings reveal a framework linking pathogenic variants affecting CREBBP IDR-dependent regulation to aberrant condensate material properties in MKHK.
Open AccessCREBBP variants underlying Menke–Hennekam syndrome exhibit histone acetyltransferase hyperactivity with divergent phase behaviors
Menke–Hennekam syndrome (MKHK) is a neurodevelopmental disease characterized by specific pathogenic regions within the transcriptional coactivator CREB-binding protein ( CREBBP ). CREBBP regulates gene expression through histone acetyltransferase (HAT) activity and involves IDR-dependent transcriptional condensates. Although domain-specific phenotypes and distinct DNA methylation episignatures have been recognized in MKHK, the underlying molecular mechanisms remain widely unclear. In this study, we identified a recurrent missense variant, p.(R1868W) [R1868W] and a novel splice variant r.5963_5969del,p.(Cys1723Thrfs*19) [C1723fs] in two families clinically diagnosed with MKHK and manifesting developmental delay, characteristic facial features, and growth impairment. R1868W and C1723fs exhibited increased auto-, nonhistone protein, and histone acetylation. Despite these shared enzymatic abnormalities, the variants promoted divergent disruption in liquid–liquid phase separation. The recurrent CBP-ID4 variant R1868W activated the formation of low-mobility aberrant nuclear condensates, whereas the C-terminal, truncating variant C1723fs, impaired condensate formation and showed diffuse nuclear localization. Treatment with the selective p300/CBP HAT inhibitor A485 partially restored condensate dynamics and fusion-relaxation behavior in R1868W. Furthermore, R1868W recruited BRD4 around condensates in an acetylation-dependent manner, which was suppressed by the BET inhibitor JQ1. Together, these findings suggest that aberrant condensate material properties arising from disrupted CREBBP IDR-dependent regulation play a critical role in the molecular pathogenesis of MKHK. Significance Statement: Pathogenic variants in specific regions of the transcriptional coactivator CREBBP underlie the Menke–Hennekam syndrome (MKHK), but its molecular basis is poorly understood. Here, we show that two CREBBP variants responsible for MKHK share a common feature of increased histone acetyltransferase (HAT) activity but disrupt liquid–liquid phase separation in distinct ways. The recurrent CBP-ID4 missense variant R1868W promoted the formation of low-mobility aberrant condensates and acetylation-dependent recruitment of BRD4, as opposed to the C-terminal truncating variant C1723fs. Notably, HAT inhibition restored condensate dynamics in R1868W, suggesting that condensate properties are reversibly regulated by enzymatic activity. These findings reveal a framework linking pathogenic variants affecting CREBBP IDR-dependent regulation to aberrant condensate material properties in MKHK.
- 10 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1586-1597
Multiomics analysis focusing on genome‐wide DNA methylation in paediatric acute promyelocytic leukaemia
Summary: We conducted a multiomics analysis of paediatric acute promyelocytic leukaemia (APL) in 36 patients enrolled in the Japanese AML‐P05 study. Targeted deep sequencing identified EP300 mutations ( n = 2) and MYC ‐internal tandem duplication (ITD) ( n = 1), which have not been previously reported in APLs. DNA methylation analysis classified 34 paediatric APLs into two groups: hypermethylation and hypomethylation. Patients in the hypermethylation group had significantly worse outcomes compared to those in the hypomethylation group (3‐year overall survival: 80% vs. 100%, p = 0.043; 3‐year event‐free survival: 73% vs. 95%, p = 0.049). Remarkably, the EBF1‐binding motif was enriched in 82.3% of the CpG sites that were differentially methylated between the hyper‐ and hypomethylation groups, and these sites were predominantly located in enhancer regions. Among the 1427 genes that were significantly differentially expressed between the two groups, EP300 was significantly downregulated in the hypermethylation group. Pathway analyses revealed global transcriptional downregulation in the hypermethylation group; however, MYC , a known EP300 ‐repressed gene, was upregulated within the G2M checkpoint. Our findings suggest a potential link among enhancer‐based epigenetic dysregulation involving DNA methylation at EBF1‐binding sites, EP300 dysfunction and MYC activation. These alterations may contribute to disease heterogeneity and prognosis in paediatric APL.
- 10 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1586-1597
Multiomics analysis focusing on genome‐wide DNA methylation in paediatric acute promyelocytic leukaemia
Summary: We conducted a multiomics analysis of paediatric acute promyelocytic leukaemia (APL) in 36 patients enrolled in the Japanese AML‐P05 study. Targeted deep sequencing identified EP300 mutations ( n = 2) and MYC ‐internal tandem duplication (ITD) ( n = 1), which have not been previously reported in APLs. DNA methylation analysis classified 34 paediatric APLs into two groups: hypermethylation and hypomethylation. Patients in the hypermethylation group had significantly worse outcomes compared to those in the hypomethylation group (3‐year overall survival: 80% vs. 100%, p = 0.043; 3‐year event‐free survival: 73% vs. 95%, p = 0.049). Remarkably, the EBF1‐binding motif was enriched in 82.3% of the CpG sites that were differentially methylated between the hyper‐ and hypomethylation groups, and these sites were predominantly located in enhancer regions. Among the 1427 genes that were significantly differentially expressed between the two groups, EP300 was significantly downregulated in the hypermethylation group. Pathway analyses revealed global transcriptional downregulation in the hypermethylation group; however, MYC , a known EP300 ‐repressed gene, was upregulated within the G2M checkpoint. Our findings suggest a potential link among enhancer‐based epigenetic dysregulation involving DNA methylation at EBF1‐binding sites, EP300 dysfunction and MYC activation. These alterations may contribute to disease heterogeneity and prognosis in paediatric APL.
- 3 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1252-1262
Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial ( JCCG AML ‐12)
Summary: RNA sequencing from 262 patients with paediatric acute myeloid leukaemia (AML) (JPLSG AML‐12) was deconvoluted employing adult single‐cell RNA‐sequencing signatures and Zeng's method, which defined five cellular hierarchy subtypes: primitive, leukaemic stem/progenitor cell (LSPC)‐Cycle, ProMono‐like, granulocyte–monocyte progenitor (GMP)‐like and intermediate. Principal component analysis revealed two main axes that distinguish paediatric from adult AML, with notable LSPC‐Cycle and ProMono‐like phenotype enrichment. LSPC‐Cycle (>25% cycling stem‐like cells) had proliferative and quiescent LSPCs, frequent French‐American‐British (FAB)‐M7 and worst prognosis (overall survival odds ratio vs. GMP‐like: 11.33). Morphology was related to the primitive (FAB‐M0), GMP‐like (M2/M4) and ProMono‐like (M5) groups. Genomic patterns aligned with hierarchy: CBFA2T3::GLIS2 , MYB::GATA1 and MECOM high expression in LSPC‐Cycle; CBFB::MYH11 , NUP98::NSD1 and NPM1 in the intermediate; and DEK::NUP214 and NUP98::KDM5A were concentrated in the primitive group. bZIP CEBPA and FLT3 ‐ITD mutations clustered in the intermediate and primitive groups. Most of RUNX1::RUNX1T1 clustered in the intermediate group, whereas KMT2A::MLLT3 hierarchy differed with MECOM expression level. Paediatric AML comprised more primitive cells, rarely with mono‐like/cDC‐like dominance. LSPC‐Cycle, FLT3 ‐ITD and NUP98::KDM5A were considered independent prognostic factors in multivariate analysis. Findings indicate the prognostic relevance of cellular hierarchy and the importance of integrating hierarchy‐specific molecular profiles for improved risk stratification and treatment formulation.
- 3 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1252-1262
Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial ( JCCG AML ‐12)
Summary: RNA sequencing from 262 patients with paediatric acute myeloid leukaemia (AML) (JPLSG AML‐12) was deconvoluted employing adult single‐cell RNA‐sequencing signatures and Zeng's method, which defined five cellular hierarchy subtypes: primitive, leukaemic stem/progenitor cell (LSPC)‐Cycle, ProMono‐like, granulocyte–monocyte progenitor (GMP)‐like and intermediate. Principal component analysis revealed two main axes that distinguish paediatric from adult AML, with notable LSPC‐Cycle and ProMono‐like phenotype enrichment. LSPC‐Cycle (>25% cycling stem‐like cells) had proliferative and quiescent LSPCs, frequent French‐American‐British (FAB)‐M7 and worst prognosis (overall survival odds ratio vs. GMP‐like: 11.33). Morphology was related to the primitive (FAB‐M0), GMP‐like (M2/M4) and ProMono‐like (M5) groups. Genomic patterns aligned with hierarchy: CBFA2T3::GLIS2 , MYB::GATA1 and MECOM high expression in LSPC‐Cycle; CBFB::MYH11 , NUP98::NSD1 and NPM1 in the intermediate; and DEK::NUP214 and NUP98::KDM5A were concentrated in the primitive group. bZIP CEBPA and FLT3 ‐ITD mutations clustered in the intermediate and primitive groups. Most of RUNX1::RUNX1T1 clustered in the intermediate group, whereas KMT2A::MLLT3 hierarchy differed with MECOM expression level. Paediatric AML comprised more primitive cells, rarely with mono‐like/cDC‐like dominance. LSPC‐Cycle, FLT3 ‐ITD and NUP98::KDM5A were considered independent prognostic factors in multivariate analysis. Findings indicate the prognostic relevance of cellular hierarchy and the importance of integrating hierarchy‐specific molecular profiles for improved risk stratification and treatment formulation.
- Open Access
- 28 November 2025
- Published by Springer Nature in Human Genome Variation
- Vol. 12 (1) , 27
DNA methylation data from Japanese patients with Rubinstein–Taybi syndrome
An episignature is a genome-wide DNA methylation pattern that is specific to each syndrome or etiologic gene. Episignature analysis helps to diagnose patients with variants of uncertain significance (VUS), but this requires positive methylation datasets from patients with a definitive diagnosis. Here we provide methylation datasets of Rubinstein–Taybi syndrome at the individual patient level, which have not been published before. This dataset increases the likelihood of determining the function of the VUS.
- 28 November 2025
- Published by Springer Nature in Human Genome Variation
- Vol. 12 (1) , 27
Open AccessDNA methylation data from Japanese patients with Rubinstein–Taybi syndrome
An episignature is a genome-wide DNA methylation pattern that is specific to each syndrome or etiologic gene. Episignature analysis helps to diagnose patients with variants of uncertain significance (VUS), but this requires positive methylation datasets from patients with a definitive diagnosis. Here we provide methylation datasets of Rubinstein–Taybi syndrome at the individual patient level, which have not been published before. This dataset increases the likelihood of determining the function of the VUS.
- Open Access
- 7 November 2025
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-12
Investigation of methylation profiles in Silver–Russell syndrome to explore episignatures
Episignatures are disease-specific, genome-wide DNA methylation patterns identified in more than 100 genetic syndromes caused by mutation of genes related to epigenetic modifiers. The utility of episignatures as a disease diagnostic tool has been demonstrated in recent years. However, studies evaluating episignatures in imprinting disorders (IDs) are very limited. We hypothesized that identifying episignatures in Silver–Russell syndrome (SRS), one of the representative IDs, could lead to the development of a new diagnostic tool for SRS. We investigated methylation profiles in patients with different molecular etiologies to clarify the presence or absence of DNA methylation episignatures in SRS. We conducted genome-wide methylation analysis (GWMA) using the HumanMethylationEPIC array in 27 patients consisting of five groups based on molecular etiologies satisfying clinical diagnostic criteria: hypomethylation of H19-differentially methylated region (DMR) (n = 9), maternal uniparental disomy chromosome 7 (n = 11), IGF2 variant (n = 3), PLAG1 variant (n = 2), and deletions including KCNQ1OT1:TSS-DMR (n = 2). We compared the methylation levels of CpGs (β values) between each group and control group (94 pediatric samples) and extracted aberrantly methylated CpGs satisfying the following criteria: (1) Bonferroni-corrected p value < 0.05, and (2) the absolute value of ∆β (|∆β|), the difference between the average β value of each ID group and controls at each probe, was above 0.1. Based on the extracted aberrantly methylated CpGs, we examined (1) aberrantly methylated patterns, (2) aberrantly methylated regions, and 3) CpG-enriched genes and their functions, shared by multiple groups. Although several CpGs were commonly hypermethylated or hypomethylated in two of the five groups, the number of CpGs was too small to form characteristic methylation patterns. Several aberrantly methylated regions, including disease-responsible DMRs of SRS, were identified in each group, but no regions common in multiple groups were identified. Previously reported aberrantly methylated regions other than disease-responsible DMRs were not identified. In addition, we found no CpG-enriched genes or their functions common in multiple groups. GWMA in SRS patients with different molecular etiologies identified no characteristic episignatures. Only methylation changes of CpGs within disease-responsible DMRs, not genome-wide methylation changes, occur in some SRS etiologies.
- 7 November 2025
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-12
Open AccessInvestigation of methylation profiles in Silver–Russell syndrome to explore episignatures
Episignatures are disease-specific, genome-wide DNA methylation patterns identified in more than 100 genetic syndromes caused by mutation of genes related to epigenetic modifiers. The utility of episignatures as a disease diagnostic tool has been demonstrated in recent years. However, studies evaluating episignatures in imprinting disorders (IDs) are very limited. We hypothesized that identifying episignatures in Silver–Russell syndrome (SRS), one of the representative IDs, could lead to the development of a new diagnostic tool for SRS. We investigated methylation profiles in patients with different molecular etiologies to clarify the presence or absence of DNA methylation episignatures in SRS. We conducted genome-wide methylation analysis (GWMA) using the HumanMethylationEPIC array in 27 patients consisting of five groups based on molecular etiologies satisfying clinical diagnostic criteria: hypomethylation of H19-differentially methylated region (DMR) (n = 9), maternal uniparental disomy chromosome 7 (n = 11), IGF2 variant (n = 3), PLAG1 variant (n = 2), and deletions including KCNQ1OT1:TSS-DMR (n = 2). We compared the methylation levels of CpGs (β values) between each group and control group (94 pediatric samples) and extracted aberrantly methylated CpGs satisfying the following criteria: (1) Bonferroni-corrected p value < 0.05, and (2) the absolute value of ∆β (|∆β|), the difference between the average β value of each ID group and controls at each probe, was above 0.1. Based on the extracted aberrantly methylated CpGs, we examined (1) aberrantly methylated patterns, (2) aberrantly methylated regions, and 3) CpG-enriched genes and their functions, shared by multiple groups. Although several CpGs were commonly hypermethylated or hypomethylated in two of the five groups, the number of CpGs was too small to form characteristic methylation patterns. Several aberrantly methylated regions, including disease-responsible DMRs of SRS, were identified in each group, but no regions common in multiple groups were identified. Previously reported aberrantly methylated regions other than disease-responsible DMRs were not identified. In addition, we found no CpG-enriched genes or their functions common in multiple groups. GWMA in SRS patients with different molecular etiologies identified no characteristic episignatures. Only methylation changes of CpGs within disease-responsible DMRs, not genome-wide methylation changes, occur in some SRS etiologies.
- Open Access
- 21 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328243
Loss-of-function mutation of NSD2 is associated with abnormal placentation accompanied by fetal growth retardation in mice
Nuclear receptor-binding SET domain-containing 2 (NSD2) is the primary enzyme responsible for the dimethylation of histone H3 lysine 36 (H3K36me2), a marker associated with active gene transcription and intergenic DNA methylation. NSD2 is required for the normal development of humans and mice; however, its function during placentation remains unknown. Using genome editing techniques, we previously established two lines of Nsd2-mutant mice that showed growth retardation and neonatal lethality. Here, we further demonstrated that the loss-of-function mutation of NSD2 caused enlargement of the mouse placenta with morphological changes during late-gestation. Nsd2-mutant placentas were significantly heavier and showed thicker fetal layers with an expanded junctional zone and dilatated maternal blood sinuses in the labyrinth compared to their wild-type littermates. Abnormal placentation was accompanied by fetal growth defects, some with edema and one with a congenital cardiovascular anomaly, which may have partially affected neonatal survival. To our knowledge, this is the first study demonstrating the physiological and pathological functions of NSD2 during placentation.
- 21 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328243
Open AccessLoss-of-function mutation of NSD2 is associated with abnormal placentation accompanied by fetal growth retardation in mice
Nuclear receptor-binding SET domain-containing 2 (NSD2) is the primary enzyme responsible for the dimethylation of histone H3 lysine 36 (H3K36me2), a marker associated with active gene transcription and intergenic DNA methylation. NSD2 is required for the normal development of humans and mice; however, its function during placentation remains unknown. Using genome editing techniques, we previously established two lines of Nsd2-mutant mice that showed growth retardation and neonatal lethality. Here, we further demonstrated that the loss-of-function mutation of NSD2 caused enlargement of the mouse placenta with morphological changes during late-gestation. Nsd2-mutant placentas were significantly heavier and showed thicker fetal layers with an expanded junctional zone and dilatated maternal blood sinuses in the labyrinth compared to their wild-type littermates. Abnormal placentation was accompanied by fetal growth defects, some with edema and one with a congenital cardiovascular anomaly, which may have partially affected neonatal survival. To our knowledge, this is the first study demonstrating the physiological and pathological functions of NSD2 during placentation.
- Open Access
Maternal Vitamin D Deficiency Is a Risk Factor for Infants’ Epigenetic Gestational Age Acceleration at Birth in Japan: A Cohort Study
Background/Objectives: The DNA methylation of neonatal cord blood can be used to accurately estimate gestational age. This is known as epigenetic gestational age. The greater the difference between epigenetic and chronological gestational age, the greater the association with an inappropriate perinatal fetal environment and development. Maternal vitamin D deficiency is common in Japan. The aim of this study was to investigate the associations between maternal serum vitamin D levels and epigenetic gestational age acceleration at birth in Japan. Methods: The data were obtained from the hospital-based birth cohort study conducted at the National Center for Child Health and Development in Tokyo, Japan. Maternal blood was collected in the second trimester to measure the serum vitamin D concentration. Cord blood was collected at birth to measure serum vitamin D and to extract DNA. DNA methylation was assessed using an Illumina methylation EPIC array. Epigenetic gestational age was calculated using the “methylclock” R package. Linear regression analysis was performed to see associations. Results: Maternal serum vitamin D levels in the second trimester were negatively associated with epigenetic gestational age acceleration at birth when calculated by Bohlin’s method (regression coefficient [95% CI]: −0.022 [−0.039, −0.005], n = 157), which was still significant after considering infants’ sex (−0.022 [−0.039, −0.005]). Cord blood serum vitamin D levels were not associated with epigenetic age acceleration. Maternal age at delivery and birth height were associated in positive and negative ways with epigenetic gestational age acceleration, respectively (0.048 [0.012, 0.085] and −0.075 [−0.146, −0.003]). Conclusions: Maternal vitamin D deficiency was related to an infant’s epigenetic gestational age acceleration at birth. These findings suggest that the association between fetal development and maternal vitamin D levels may involve the fetal epigenetic regulation of the fetus.
Open AccessMaternal Vitamin D Deficiency Is a Risk Factor for Infants’ Epigenetic Gestational Age Acceleration at Birth in Japan: A Cohort Study
Background/Objectives: The DNA methylation of neonatal cord blood can be used to accurately estimate gestational age. This is known as epigenetic gestational age. The greater the difference between epigenetic and chronological gestational age, the greater the association with an inappropriate perinatal fetal environment and development. Maternal vitamin D deficiency is common in Japan. The aim of this study was to investigate the associations between maternal serum vitamin D levels and epigenetic gestational age acceleration at birth in Japan. Methods: The data were obtained from the hospital-based birth cohort study conducted at the National Center for Child Health and Development in Tokyo, Japan. Maternal blood was collected in the second trimester to measure the serum vitamin D concentration. Cord blood was collected at birth to measure serum vitamin D and to extract DNA. DNA methylation was assessed using an Illumina methylation EPIC array. Epigenetic gestational age was calculated using the “methylclock” R package. Linear regression analysis was performed to see associations. Results: Maternal serum vitamin D levels in the second trimester were negatively associated with epigenetic gestational age acceleration at birth when calculated by Bohlin’s method (regression coefficient [95% CI]: −0.022 [−0.039, −0.005], n = 157), which was still significant after considering infants’ sex (−0.022 [−0.039, −0.005]). Cord blood serum vitamin D levels were not associated with epigenetic age acceleration. Maternal age at delivery and birth height were associated in positive and negative ways with epigenetic gestational age acceleration, respectively (0.048 [0.012, 0.085] and −0.075 [−0.146, −0.003]). Conclusions: Maternal vitamin D deficiency was related to an infant’s epigenetic gestational age acceleration at birth. These findings suggest that the association between fetal development and maternal vitamin D levels may involve the fetal epigenetic regulation of the fetus.
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
Maternal Vitamin D Deficiency is a Risk Factor for Infants’ Epigenetic Gestational Age Acceleration at Birth in Japan: A Cohort Study
Background/Objectives: Vitamin D deficiency has been frequently observed in every generation worldwide. Pregnant women are no exception. The associations between maternal vitamin D status and fetal growth, immune system, or metabolism are reported. These infant characteristics are also reported to be associated with epigenetic gestational age at birth. Epigenetic gestational age acceleration at birth longitudinally relates to infant health. This study aimed to investigate the associations between maternal serum vitamin D levels and infants' epigenetic gestational age acceleration in Japan. Methods: The data were obtained from the hospital-based birth cohort study conducted at the National Center for Child Health and Development in Tokyo, Japan. Maternal blood was collected in the 2nd trimester to measure serum vitamin D concentration. Cord blood was collected at birth to measure serum vitamin D and to extract DNA. DNA methylation was assessed using Illumina methylation EPIC array. Epigenetic gestational age was calculated using “methylclock” R package. Linear regression analysis was performed to see associations. Results: Maternal serum vitamin D levels in the 2nd trimester were negatively associated with epigenetic gestational age acceleration at birth when calculated by Bohlin’s method (regression coefficient [95% CI]: -0.022 [-0.039, -0.005], n = 157), which was still significant after considering infants sex (-0.022 [-0.039, -0.005]). Cord blood serum vitamin D levels were not associated with epigenetic age acceleration. Maternal age at delivery and birth height were associated in positive and negative ways with epigenetic gestational age acceleration, respectively (0.048 [0.012, 0.085] and -0.075 [-0.146, -0.003]). Conclusions: Maternal vitamin D deficiency was related to an infant’s epigenetic gestational age acceleration at birth. These results indicate that maternal vitamin D epigenetically programs fetal development which may affect an infant's health after birth.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessMaternal Vitamin D Deficiency is a Risk Factor for Infants’ Epigenetic Gestational Age Acceleration at Birth in Japan: A Cohort Study
Background/Objectives: Vitamin D deficiency has been frequently observed in every generation worldwide. Pregnant women are no exception. The associations between maternal vitamin D status and fetal growth, immune system, or metabolism are reported. These infant characteristics are also reported to be associated with epigenetic gestational age at birth. Epigenetic gestational age acceleration at birth longitudinally relates to infant health. This study aimed to investigate the associations between maternal serum vitamin D levels and infants' epigenetic gestational age acceleration in Japan. Methods: The data were obtained from the hospital-based birth cohort study conducted at the National Center for Child Health and Development in Tokyo, Japan. Maternal blood was collected in the 2nd trimester to measure serum vitamin D concentration. Cord blood was collected at birth to measure serum vitamin D and to extract DNA. DNA methylation was assessed using Illumina methylation EPIC array. Epigenetic gestational age was calculated using “methylclock” R package. Linear regression analysis was performed to see associations. Results: Maternal serum vitamin D levels in the 2nd trimester were negatively associated with epigenetic gestational age acceleration at birth when calculated by Bohlin’s method (regression coefficient [95% CI]: -0.022 [-0.039, -0.005], n = 157), which was still significant after considering infants sex (-0.022 [-0.039, -0.005]). Cord blood serum vitamin D levels were not associated with epigenetic age acceleration. Maternal age at delivery and birth height were associated in positive and negative ways with epigenetic gestational age acceleration, respectively (0.048 [0.012, 0.085] and -0.075 [-0.146, -0.003]). Conclusions: Maternal vitamin D deficiency was related to an infant’s epigenetic gestational age acceleration at birth. These results indicate that maternal vitamin D epigenetically programs fetal development which may affect an infant's health after birth.